Abstract Library

#2906 Change of Lactate Transporter (MCT4) Expression in Pancreatic Microadenomas and Stages of Pancreatic Neuroendocrine Tumors

Introduction: Metabolic changes are observed in early and late stages of Pancreatic Neuroendocrine Tumors (PanNET) in mouse models. In human PanNET, RNA-expression analysis showed changes in glucose metabolism in more aggressive PanNET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Bräutigam K

Authors: Straub J, Bräutigam K, Di Domenico A, Galván J, Maire R,

Keywords: metabolism, microadenoma, immunohistochemistry, pancreas, tumor, mct4, relapse,

#838 Succinate Dehydrogenase Subunit B (SDHB) Immunohistochemistry Should Not Replace Clinical Genetic Testing for SDHx Mutations in Patients with Pheochromocytoma and Paraganglioma

Introduction: Mutations in any of the subunits of the succinate dehydrogenase (SDH) complex predispose to PCC/PGL. Knowing the germline mutation is important for surveillance for recurrence, metastatic disease or more primary tumors and for screening affected family members. Expression of SDHB protein by immunohistochemistry (IHC) has been proposed as a surrogate marker for SDHx mutation status, with absent or decreased expression of SDHB suggesting the presence of a germline SDHB mutation or disruption of the SDH complex by mutation in another subunit.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Fishbein L, Bennett B, Merrill S, Cohen D, LiVolsi V,

Keywords: Pheo, succinate dehydrogenase,

#473 Succinate Dehydrogenase (SDHB): A New Marker of Malignancy in Midgut Carcinoids?

Introduction: The immunoistochemical (IHC) loss of SDHB expression was reported as a surrogate marker of malignancy in sporadic and familial pheocromocytomas/paragangliomas. SDHB loss is supposed to be tumorigenic (activation hypoxia signals).

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Milione M, Pusceddu S, Mazzaferro V, Buzzoni R, De Braud F,

Keywords: SDHB,

#246 SDHB Loss Predicts Malignancy in Pheochromocytomas/Sympathethic Paragangliomas, but Not Through Hypoxia Signalling

Introduction: To date there is no reliable histopathological marker of malignancy for pheochromocytomas/sympathetic paragangliomas (PCC/PGL). It is well-known that PCC/PGL in the hereditary context of an SDHB germline mutation very often metastasize. The immunohistochemical loss of SDHB expression was recently shown to be a surrogate marker for the presence of an SDH germline mutation in PCC/PGL. SDHB loss is supposed to be tumorigenic via activation of hypoxia signals.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Schmitt A, Blank A, Korpershoek E, van Nederveen F, Rudolph T,

Keywords: SDHB loss, immunohistochemistry, pheochromocytoma, paraganglioma, malignancy, hypoxia,

#67 Interest of combined chromogranin A and pancreatic polypeptide for diagnosis and follow-up of gastroenteropancreatic endocrine carcinoma

Introduction: Assessment of tumor burden changes is essential for the management of well-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEPNET). Chromogranin A (CgA) is the principal tumor marker for such tumors; however, its use to evaluate morphological tumor progression is not validated. Combined CgA and pancreatic polypeptide (PP) may increase sensitivity in the diagnosis of GEP-NET.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: WALTER T

Authors: Walter T, Chardon L, Caffin A, Chopin-Laly X, Cohen R,

Keywords: polypeptide pancreatic, chromogranin A, gastroenteropancreatic neuroendocrine carcinoma, carcinoid, islet cell carcinoma, surrogate marker,